2967-72-8

Basic information

• Product Name: 3-(2-FLUORO-PHENOXY)-PROPIONIC ACID
• Synonyms: Propionicacid, 3-(o-fluorophenoxy)- (6CI,8CI);3-(2-Fluorophenoxy)propanoic acid;3-(2-Fluorophenoxy)propionic acid
• CAS NO: 2967-72-8
• Molecular Formula: C₉H₉FO₃
• Molecular Weight: 184.17
• Mol File: 2967-72-8.mol

Chemical Properties

• Melting Point: 109-111 °C
• Boiling Point: 282.5 °C at 760 mmHg
• Flash Point: 124.6 °C
• Appearance: /
• Density: 1.267 g/cm³
• Vapor Pressure: 0.00158mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: 2-8°C
• PKA: 4.13±0.10(Predicted)
• CAS DataBase Reference: 3-(2-FLUORO-PHENOXY)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-FLUORO-PHENOXY)-PROPIONIC ACID(2967-72-8)
• EPA Substance Registry System: 3-(2-FLUORO-PHENOXY)-PROPIONIC ACID(2967-72-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 2967-72-8(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
3-(2-Fluoro-Phenoxy)-Propionic Acid is used as a research compound for studying its chemical properties and potential interactions with other molecules. Its unique structure may offer insights into new chemical reactions or pathways.
Used in Manufacturing:
3-(2-Fluoro-Phenoxy)-Propionic Acid is used as an intermediate in the synthesis of more complex organic compounds, potentially contributing to the development of new materials or products.
Used in Pharmaceutical Industry:
3-(2-Fluoro-Phenoxy)-Propionic Acid is used as a potential starting material for the development of new drugs. Its structural characteristics may provide a basis for designing novel therapeutic agents, although more research is required to determine its suitability and efficacy in this context.

InChI:InChI=1/C9H9FO3/c10-7-3-1-2-4-8(7)13-6-5-9(11)12/h1-4H,5-6H2,(H,11,12)

Upstream product

• 111140-91-1 3-(2-fluorophenoxy)propanenitrile 
• 590-92-1 3-Bromopropionic acid 
• 367-12-4 2-fluorophenol 
• 57-57-8 β-Propiolactone 
• 145073-40-1 3-(2-fluorophenoxy)-1-propanol 

Downstream Products

• 911826-26-1 (R)-2-(2-(2,4-dimethoxybenzylamino)-4-fluorophenylamino)-9-(8-fluorochroman-4-yl)-7H-purin-8(9H)-one 
• 911826-25-0 (R)-N₂-(2-(2,4-dimethoxybenzylamino)-4-fluorophenyl)-N₄-(8-fluorochroman-4-yl)-5-nitropyrimidine-2,4-diamine 
• 1026790-40-8 (R)-N₂-(2-(2,4-dimethoxybenzylamino)-4-fluorophenyl)-N₄-(8-fluorochroman-4-yl)pyrimidine-2,4,5-triamine 
• 1026790-41-9 (R)-2-(2-amino-4-fluorophenylamino)-9-(8-fluorochroman-4-yl)-7H-purin-8(9H)-one 
• 1003887-62-4 (S)-8-fluorochroman-4-amine 
• 791043-28-2 8-fluorochroman-4-amine 
• 750571-31-4 (R)-8-fluorochroman-4-amine 
• 188826-32-6 5-fluoro-2,3-dihydro-4H-chromen-4-one 
• 245127-15-5 methyl 3-(2-fluorophenoxy)propanoate 
• 1392286-18-8 4-(2-fluorophenoxy)-2-methylbutan-2-ol 
• 1392286-17-7 4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide 
• 111141-00-5 8-fluoro-2,3-dihydro-4-H-1-benzopyran-4-one 

Relevant articles and documents

Condensed derivatives of imidazole useful as pharmaceuticals

The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application

The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R3) at the para-position of the P1′ benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC50s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.

SPIROAMINODIHYDROTHIAZINE DERIVATIVES

A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer- type dementia.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:

7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula (III).

TRICYCLIC AMINOALCOHOLS, METHODS FOR PRODUCING THE SAME AND THEIR USE AS ANTI-INFLAMMATORY AGENTS

The invention relates to the tricyclic aminoalcohols of general formula (I), to methods for producing the same and to their use as anti-inflammatory agents.

ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS

The invention relates to alkylidene tetrahydronaphthalene derivatives of general formula (I), to methods for their production and to their use as anti-inflammatory agents.

PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).

Spiro hydantoin aldose reductase inhibitors

Sorbitol formation from glucose, catalyzed by the enzyme aldose reductase, is believed to play a role in the development of certain chronic complications of diabetes mellitus. Spiro hydantoin derived from five- and six-membered ketones fused to an aromatic ring or ring system inhibit aldose reductase isolated from calf lens. In vivo these compounds are potent inhibitors of sorbitol formation in sciatic nerves of streptozotocinized rats. Optimum in vivo activity is reached in spiro hydantoins derived from 6-halogenated 2,3-dihydro-4H-1-benzopyran-4-ones (4-chromanones). In 2,4-dihydro-6-fluorospirol[4H-1-benzopyran-4,4'-imidazolidine]-2',5'- ione, the activity resides exclusively in the 4S isomer, compound 115 (CP-45,634, USAN: sorbinil). This compound is currently being used to test, in humans, the value of aldose reductase inhibitors in the therapy of diabetic complications.